Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03001830 · ClinicalTrials.gov registry record · Phase 1

Gene Therapy for Haemophilia A.

A Phase 1 study of Hemophilia A, sponsored by University College, London.

Active
Registry status
Phase 1
Development phase
14
Enrollment target
4
Study locations

NCT03001830: Active Phase 1 study of Hemophilia A, sponsored by University College, London.

NCT03001830 is a Phase 1 study of Hemophilia A that is active but no longer recruiting, run by University College, London. The registered enrollment target is 14 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03001830, a Phase 1 study of Hemophilia A, is active but no longer recruiting, sponsored by University College, London.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
14 participants
Enrollment target
4
Study locations

Study Summary

The GO-8 study focuses on assessing safety and efficacy of gene therapy for patients with severe haemophilia A

Primary Outcome

Toxicity will be assessed according to CTCAE, version 4.03 based on the monitoring schedule which comprises a number of clinical and laboratory evaluations

Conditions Studied

Hemophilia A

Interventions

  • BIOLOGICAL AAV2/8-HLP-FVIII-V3

Study Locations (4)

Idaho

  • St. Luke'S Regional Medical Center, Ltd - Boise

Kentucky

  • University of Kentucky - Lexington

Tennessee

  • St Jude's Children's Research Hospital - Memphis

Other

  • Royal Free Hospital - London

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2017-06-14
Est. Completion 2029-12
Phase Phase 1
University College, London

8 total trials

What the registry record for NCT03001830 still lists

NCT03001830 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which AAV2/8-HLP-FVIII-V3 is the first listed.

NCT03001830 reports a single indexed study location in Idaho, Kentucky, Tennessee.

Frequently Asked Questions

What is clinical trial NCT03001830 about?

NCT03001830 is a clinical study titled "Gene Therapy for Haemophilia A.". The GO-8 study focuses on assessing safety and efficacy of gene therapy for patients with severe haemophilia A

What is the current status of trial NCT03001830?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2017-06-14. Estimated completion is 2029-12.

What conditions does trial NCT03001830 study?

This clinical trial studies the following conditions: Hemophilia A.

What interventions are being tested in trial NCT03001830?

The interventions under investigation include: AAV2/8-HLP-FVIII-V3 (BIOLOGICAL).

Who is sponsoring clinical trial NCT03001830?

This trial is sponsored by University College, London, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03001830 being conducted?

This trial has 4 study locations across Idaho, Kentucky, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hemophilia A

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03001830's enrollment target sits among peer trials

14 34th of 42 higher than 8 of 42 other Hemophilia A trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Related registry views

Source: ClinicalTrials.gov NCT03001830, the US trial registry maintained by the National Library of Medicine. NCT03001830 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.